Researchers plan brain scans on about 180 people making food and money choices to see if GLP-1 use shifts the reward system away from instant gratification.
Recap by typeshit. Full story at WTKR.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
One mother tells ABC News she got pregnant a month after starting a GLP-1. Doctors note the drugs aren't a fertility treatment and advise stopping two months before trying to conceive.
The clinic explains the investigational drug acts on GLP-1, GIP and glucagon receptors, which play roles in appetite, blood sugar and energy use.
Loading…